PMN (ProMIS Neurosciences) 3-Year Share Buyback Ratio: -84.40% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PMN ProMIS Neurosciences Inc PMN
35 GF Score
Price $13.35
! 1 Warning Sign
View Full Analysis

What is ProMIS Neurosciences 3-Year Share Buyback Ratio?

ProMIS Neurosciences PMN -2.73% 35 3-Year Share Buyback Ratio is -84.40 as of Jun. 2026. GuruFocus rates PMN with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,189 Biotechnology companies, ProMIS Neurosciences ranks worse than 89.66% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. ProMIS Neurosciences's current 3-Year Share Buyback Ratio was -84.40%.

The historical rank and industry rank for ProMIS Neurosciences's 3-Year Share Buyback Ratio or its related term are showing as below:

PMN' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -84.4   Med: -20.4   Max: -4
Current: -84.4

During the past 13 years, ProMIS Neurosciences's highest 3-Year Share Buyback Ratio was -4.00%. The lowest was -84.40%. And the median was -20.40%.

PMN's 3-Year Share Buyback Ratio is ranked worse than
89.66% of 1189 companies
in the Biotechnology industry
Industry Median: -11.8 vs PMN: -84.40

ProMIS Neurosciences (NAS:PMN) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


ProMIS Neurosciences 3-Year Share Buyback Ratio Related Terms


PMN vs GNLX, NTHI, VXRT: 3-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, ProMIS Neurosciences's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProMIS Neurosciences 3-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's 3-Year Share Buyback Ratio falls into.


PMN
35GF Score
ProMIS Neurosciences Inc PMN
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProMIS Neurosciences 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -84.40 mean?
ProMIS Neurosciences (PMN) has a 3-Year Share Buyback Ratio of -84.40 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for ProMIS Neurosciences and its competitors. According to the industry distribution chart, ProMIS Neurosciences ranks #1066 out of 1189 companies in the Biotechnology industry, placing it in the top 89.7%.
Is ProMIS Neurosciences' 3-Year Share Buyback Ratio too high?
ProMIS Neurosciences' current 3-Year Share Buyback Ratio is -84.40. Based on the distribution chart, ProMIS Neurosciences ranks #1066 out of 1189 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ProMIS Neurosciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' 3-Year Share Buyback Ratio compare to GNLX and NTHI?
According to the Biotechnology industry distribution chart, ProMIS Neurosciences ranks #1066 out of 1189 companies for 3-Year Share Buyback Ratio. This places ProMIS Neurosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for ProMIS Neurosciences and its competitors. ProMIS Neurosciences's current 3-Year Share Buyback Ratio is -84.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current 3-Year Share Buyback Ratio of -84.40. The current 3-Year Share Buyback Ratio is -84.40. ProMIS Neurosciences' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current 3-Year Share Buyback Ratio is -84.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProMIS Neurosciences Business Description

Other Exchanges 23J:Germany
Address 1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
35GF Score

Get the complete analysis for PMN

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.35
Price